Category Press Releases

Stelo Adds

Stelo Adds New Smart Meal Logging Features to Strengthen Personal Glucose Management

Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management Dexcom, Inc. the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their…

Read MoreStelo Adds New Smart Meal Logging Features to Strengthen Personal Glucose Management

Nubeqa™ (Darolutamide) Secures Third Approval in China for Treatment of Advanced Prostate Cancer in Men

Nubeqa™ (Darolutamide) Gains Third Approval in China for Treatment of Advanced Prostate Cancer in Men The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with androgen deprivation therapy (ADT) for…

Read MoreNubeqa™ (Darolutamide) Secures Third Approval in China for Treatment of Advanced Prostate Cancer in Men

Bio-Techne Launches Fully Defined Synthetic Solution to Expand 3D Stem Cell and Organoid Culture Portfolio

Bio-Techne Broadens 3D Stem Cell and Organoid Culture Offerings with a Fully Defined, Synthetic Matrix Alternative Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ Synthetic Hydrogel, a fully defined…

Read MoreBio-Techne Launches Fully Defined Synthetic Solution to Expand 3D Stem Cell and Organoid Culture Portfolio

AstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals

AstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across…

Read MoreAstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals

Glaukos Announces FDA Approval of NDA Supplement Permitting Re-Administration of iDose® TR

Glaukos Announces FDA Approval for Re-Administration of iDose® TR Glaukos Corporation, an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration…

Read MoreGlaukos Announces FDA Approval of NDA Supplement Permitting Re-Administration of iDose® TR
Teva

Will Forte Partners with Teva for “Honestly HD” Campaign to Raise Awareness About Huntington’s Disease

Will Forte Partners with Teva to Launch “Honestly HD”—A Candid Conversation About Huntington’s Disease Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to…

Read MoreWill Forte Partners with Teva for “Honestly HD” Campaign to Raise Awareness About Huntington’s Disease
Neurocrine

Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults

Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults Neurocrine Biosciences, Inc. today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation,…

Read MoreNeurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults
WuXi Biologics

WuXi Biologics, HanchorBio Partner on Next-Gen Fusion Proteins

WuXi Biologics and HanchorBio Forge Strategic Partnership to Advance Next-Gen Bi- and Multi-Functional Fusion Proteins WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies…

Read MoreWuXi Biologics, HanchorBio Partner on Next-Gen Fusion Proteins

Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma

Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma GSK plc today announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of patients…

Read MoreTrelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma